Tricida, Inc. (TCDA)

11.72 +0.32 (+2.81%) As of 10:12AM EDT. Market open.

Tricida, Inc.

7000 Shoreline Court
Suite 201
South San Francisco, CA 94080
United States
415 429 7800
https://www.tricida.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 57

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Gerrit Klaerner Ph.D.	Founder, Pres, CEO & Exec. Director	992.55k	N/A	1972
Mr. Geoffrey M. Parker	COO, CFO & Exec. VP	656.28k	N/A	1965
Mr. Robert L. McKague J.D.	Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer	570.51k	N/A	N/A
Dr. Dawn Parsell Ph.D.	Exec. VP of Clinical Devel.	649.17k	N/A	1962
Ms. Annie Yoshiyama	VP of Fin. & Chief Accounting Officer	N/A	N/A	1983
Jackie Cossmon	VP of Investor Relations & Communications	N/A	N/A	N/A
Mr. Edward J. Hejlek Esq., J.D.	Exec. VP of Intellectual Property	N/A	N/A	1956

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Corporate Governance

Tricida, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.